ROYAL BANK OF CANADA - FUSION PHARMACEUTICALS INC ownership

Quarter-by-quarter ownership
ROYAL BANK OF CANADA ownership history of FUSION PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$11,000
+22.2%
4,204
+128.6%
0.00%
Q2 2023$9,000
+12.5%
1,839
-16.5%
0.00%
Q1 2023$8,000
+166.7%
2,203
+159.2%
0.00%
Q4 2022$3,0000.0%8500.0%0.00%
Q3 2022$3,000
+50.0%
8500.0%0.00%
Q2 2022$2,000
-71.4%
8500.0%0.00%
Q1 2022$7,000
+75.0%
8500.0%0.00%
Q4 2021$4,000
-78.9%
850
-63.8%
0.00%
Q3 2021$19,000
+111.1%
2,350
+104.3%
0.00%
Q2 2021$9,000
+200.0%
1,150
+267.4%
0.00%
Q1 2021$3,000
-25.0%
313
+4.3%
0.00%
Q4 2020$4,0000.0%3000.0%0.00%
Q3 2020$4,000
-20.0%
3000.0%0.00%
Q2 2020$5,0003000.00%
Other shareholders
FUSION PHARMACEUTICALS INC shareholders Q4 2023
NameSharesValueWeighting ↓
JOHNSON & JOHNSON 3,670,516$9,140,0002.34%
Pivotal bioVenture Partners Investment Advisor LLC 1,560,982$3,887,0001.96%
ADAMS STREET PARTNERS LLC 2,947,809$7,340,0001.91%
Sio Capital Management, LLC 260,448$649,0000.24%
Orbimed Advisors 3,224,770$8,030,0000.15%
Artal Group S.A. 750,000$1,868,0000.10%
TPG GP A, LLC 2,551,794$6,354,0000.10%
Perceptive Advisors 1,052,445$2,621,0000.08%
Rock Springs Capital Management LP 809,854$2,017,0000.06%
FEDERATED HERMES, INC. 3,124,100$7,779,0000.02%
View complete list of FUSION PHARMACEUTICALS INC shareholders